What is HC Wainwright’s Estimate for ELVN Q2 Earnings?

Posted by Brian Himes on May 13th, 2026

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Equities researchers at HC Wainwright raised their Q2 2026 earnings estimates for shares of Enliven Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.41) per share for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($1.77) EPS.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06.

ELVN has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Mizuho increased their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Guggenheim started coverage on Enliven Therapeutics in a report on Tuesday. They set a “buy” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $53.17.

View Our Latest Stock Analysis on Enliven Therapeutics

Enliven Therapeutics Stock Up 6.8%

NASDAQ ELVN opened at $42.30 on Wednesday. The firm has a market cap of $2.58 billion, a P/E ratio of -25.33 and a beta of 0.32. The company’s 50 day moving average is $37.73 and its 200-day moving average is $27.75. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $48.53.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at $1,508,580. This represents a 16.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. This represents a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP grew its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.